PT - JOURNAL ARTICLE AU - Yutaro Mori AU - Corby Fink AU - Takaharu Ichimura AU - Keisuke Sako AU - Makiko Mori AU - Nathan N. Lee AU - Philipp Aschauer AU - Krishna M. Padmanabha Das AU - SoonGweon Hong AU - Minsun Song AU - Robert F. Padera, Jr. AU - Astrid Weins AU - Luke P. Lee AU - Mahmoud L. Nasr AU - Gregory A. Dekaban AU - Jimmy D. Dikeakos AU - Joseph V. Bonventre TI - KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney AID - 10.1101/2020.09.16.20190694 DP - 2022 Jan 01 TA - medRxiv PG - 2020.09.16.20190694 4099 - http://medrxiv.org/content/early/2022/01/11/2020.09.16.20190694.short 4100 - http://medrxiv.org/content/early/2022/01/11/2020.09.16.20190694.full AB - SARS-CoV-2 precipitates respiratory distress by infection of airway epithelial cells and is often accompanied by acute kidney injury. We report that Kidney Injury Molecule-1/T cell immunoglobulin mucin domain 1 (KIM-1/TIM-1) is expressed in lung and kidney epithelial cells in COVID-19 patients and is a receptor for SARS-CoV-2. Human and mouse lung and kidney epithelial cells express KIM-1 and endocytose nanoparticles displaying the SARS-CoV-2 spike protein (virosomes). Uptake was inhibited by anti-KIM-1 antibodies and TW-37, a newly discovered inhibitor of KIM-1-mediated endocytosis. Enhanced KIM-1 expression by human kidney tubuloids increased uptake of virosomes. KIM-1 binds to the SARS-CoV-2 Spike protein in vitro. KIM-1 expressing cells, not expressing angiotensin-converting enzyme 2 (ACE2), are permissive to SARS-CoV-2 infection. Thus, KIM-1 is an alternative receptor to ACE2 for SARS-CoV-2. KIM-1 targeted therapeutics may prevent and/or treat COVID-19.Competing Interest StatementJ.V.B. and T.I. are co-inventors on KIM-1 patents assigned to Partners Healthcare. J.V.B and T.I. have filed a patent for the discovery of TW-37 as inhibitor of KIM-1 to alleviate COVID-19. J.V.B. is a consultant to Aldeyra, Angion, Sarepta and Seattle Genetics, and owns equity in Goldfinch, Innoviva, MediBeacon, DxNow, Verinano, and Autonomous Medical Devices. J.V.B.'s interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.Funding StatementThis work was supported by grants from the National Institute of Health/NCATS/NIDDK UH3TR002155 (J.V.B. & L.P.L.); NIDDK 2R01DK072381 (J.V.B. & L.P.L.), R37DK039773 (J.V.B.) and Postdoctoral Fellowship from Uehara Memorial Foundation (to Y.M.), the Overseas Research Fellowships from Japan Society for the Promotion of Science (to Y.M.) and the Canadian Institutes of Health Research (to G.A.D. and J.D.D.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Institutional Review Board of the Ethics Committee of Partners HealthcareI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the relevant data are available from the corresponding authors upon reasonable request.